Why Is Women Health-Focused Organon Stock Trading Higher On Thursday?

Zinger Key Points
  • Organon's women's Health franchise also benefited from a strong performance of oral contraceptives.
  • Established Brands saw a 3% increase in revenue despite the challenging operating environment in China.

Thursday, Organon & Co OGN reported an 8% Y/Y increase in the fourth quarter of 2023, reaching around $1.6 billion, beating the consensus of $1.55 billion.

Women’s Health revenue increased by 7% as reported and 8% ex-FX, driven by strong growth in fertility products, particularly Follistim AQ. 

Follistim grew 63% ex-FX due to increased demand in the U.S. that was largely tied to onboarding a new customer, and volume recovery in China tied to fertility patients returning to clinics following abating COVID-19 concerns.

Women’s Health franchise also benefited from the strong performance of oral contraceptives. However, challenges included a decline in Nexplanon and NuvaRing due to competitive pressures. 

Biosimilar revenue surged by 49% as reported and 48% ex-FX, with significant contributions from Ontruzant and Renflexis. Established Brands saw a 3% increase in revenue despite the challenging operating environment in China.

For the fourth quarter of 2023, Organon reported a gross margin of 60.3% on an adjusted basis. 

Adjusted EBITDA margin improved to 28.1%, reflecting lower operating expenses and foreign exchange losses. 

The company reported adjusted EPS of $0.88, beating the consensus of $0.83.

Guidance: For the fiscal year 2024, Organon expects constant currency revenue growth in the low-single-digit range. It forecasts revenue of $6.2 billion-$6.5 billion versus the consensus of $6.40 billion.

Organon expects a stable to improving Adjusted EBITDA margin with a guidance range of 31.0%-33.0%.

Price Action: OGN shares are up 13.70% at $18.61 on the last check Thursday.

Image by Gabriela Sanda from Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!